Immunological compositions as cancer biomarkers and/or therapeutics
The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.
1. A method of determining a response of a subject to an anti-cancer treatment that comprises an anti-tumor antigen antibody, the method comprising:
(a) detecting, in a sample from said subject, an antibody that reacts immunologically with said anti-tumor antigen antibody, and
(b) further treating said subject with said anti-tumor antigen antibody when step (a) reveals the presence of an antibody that reacts immunologically with said anti-tumor antigen antibody.
2. The method of claim 1 , wherein said antibody that reacts immunologically with said anti-tumor antigen antibody is further defined as detecting an anti-idiotypic antibody that reacts immunologically with the variable region of said anti-tumor antigen antibody, wherein the presence of said anti-idiotypic antibody indicates that the subject will respond to said further treatment.
3. The method of claim 1 , wherein the antibody that reacts immunologically with an anti-tumor antigen antibody comprises a polyclonal antibody, a monoclonal antibody, a recombinant ScFv (single chain fragment variable) antibody fragment, Fv, VL or VH fragment, a Fab idiotypic antibody fragment, or an anti-idiotypic antibody fragment.
4. The method of claim 1 , wherein said subject has not previously received said treatment.
5. The method of claim 1 , wherein said subject has previously received said treatment.
6. The method of claim 1 , wherein said tumor antigen comprises HER2, (EGFR) HER1. HER3, HER4, VEGFR, CD20, or EpCAM.
7. The method of claim 1 , wherein said anti-tumor antigen antibody comprises trastuzumab, cetuximab, rituximab, bevacizumab, edrecolomab, panitumumab or alemtuzumab.